Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).
Aim(s): The primary outcome was to determine biochemical and symptomatic improvement after initiating Telotristat. The secondary outcome was to define the demographic of patients at King’s College Hospital typically started on Telotristat therapy.
Materials and methods: We performed a retrospective chart-review study of 15 patients diagnosed with metastatic small bowel neuroendocrine tumours with symptoms of carcinoid syndrome. Medical notes and clinic letters were reviewed for patient-reported symptoms, biochemical marker levels and imaging results.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Doctor Shweta Hota
To read results and conclusion, please login ...
Further abstracts you may be interested in